Physician

Ahmet Afsin Oktay, M.D.

According to 2025 Medicare claims, Ahmet Oktay, M.D. (NPI: 1457627275) practices cardiology in the Chicago-Naperville-Schaumburg, IL market, with the plurality of this provider's patient population coming from Cook, IL. This provider's primary affiliated billing organization is RUSH UNIVERSITY MEDICAL GROUP (NPI: 1093819542; TIN: 91-1780160) and primary practice location at 60612-3883. Oktay is affiliated with the Mass General Brigham ACO, LLC (ACO ID: A4641) and CVS Accountable Care Organization, Inc. (ACO ID: D0061), participating under both the MSSP and REACH models.

Oktay's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,023 traditional Medicare patients, billed 2,207 HCPCS/CPT codes, and received $97,926 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,490 prescription claims across 404 beneficiaries totaling $974,112 in drug costs, led by Vyndamax (Tafamidis). Open Payments data shows 2 records totaling $250. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $44,872 and ending at $97,926. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $13,822 to $974,112. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	663	1,124	$44,872
2018	1,794	3,544	$147,004
2019	1,882	3,654	$148,235
2020	1,308	2,755	$122,417
2021	1,808	4,057	$173,450
2022	866	1,679	$72,946
2023	1,086	2,324	$99,506
2024	1,023	2,207	$97,926

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	67	245	$13,822
2016	103	424	$21,222
2017	107	497	$31,597
2018	170	1,039	$97,238
2019	244	1,756	$209,905
2020	319	2,113	$313,185
2021	431	3,156	$607,450
2022	444	1,796	$623,333
2023	338	1,825	$787,937
2024	404	2,490	$974,112

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	167	217	$69
78431	Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan	115	115	$65
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	418	427	$59
93016	Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician	159	160	$16
93018	Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician	168	169	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndamax	Tafamidis	16	600	$428,374
Jardiance	Empagliflozin	92	6,510	$120,900
Entresto	Sacubitril/Valsartan	79	4,162	$90,396
Eliquis	Apixaban	44	2,888	$55,372
Repatha Sureclick	Evolocumab	37	2,716	$53,845

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$250	Novo Nordisk Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ahmet Afsin Oktay, M.D.?

Tedicare shows public-source Medicare data for Ahmet Afsin Oktay, M.D. (NPI 1457627275), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ahmet Afsin Oktay, M.D. have ACO affiliation data?

Ahmet Afsin Oktay, M.D. is shown with ACO affiliation data for Mass General Brigham ACO, LLC (MSSP, ACO ID A4641) and CVS Accountable Care Organization, Inc. (REACH, ACO ID D0061).

What billing organization is linked to Ahmet Afsin Oktay, M.D.?

Ahmet Afsin Oktay, M.D. is linked to RUSH UNIVERSITY MEDICAL GROUP (billing NPI 1093819542) in the available physician profile data.

Does Ahmet Afsin Oktay, M.D. have Open Payments data?

Ahmet Afsin Oktay, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.